# Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes

> **NCT02583438** · PHASE4 · UNKNOWN · sponsor: **Beijing Chao Yang Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Type 2 Diabetes
- Obesity

## Interventions

- **DRUG:** Saxagliptin (Bristol-Myers Squibb Company)

## Key facts

- **NCT ID:** NCT02583438
- **Lead sponsor:** Beijing Chao Yang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2017-10
- **Final completion:** 2018-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2015-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02583438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02583438, "Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02583438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*